HealthEquity, Inc

HealthEquity trades at a P/E of 32.3, nearly double the typical technology services multiple, despite sitting at a neutral RSI of 50.6 and well below its 52-week high. The elevated valuation suggests the market is pricing in substantial growth expectations for its health savings account platform, yet the stock's distance from its peak leaves room for either a retest or continued consolidation. With only 5.66% short interest, there's minimal squeeze catalyst, and the current positioning implies the market has already digested recent gains—leaving success dependent on whether the company can justify its premium valuation through execution rather than sentiment.